- Home
- QSI vs KROS Comparison
QSI vs KROS Comparison
Compare QSI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- KROS
- Stock Information
- Founded
- QSI 2013
- KROS 2015
- Country
- QSI United States
- KROS United States
- Employees
- QSI N/A
- KROS N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- KROS Health Care
- Exchange
- QSI Nasdaq
- KROS Nasdaq
- Market Cap
- QSI 633.2M
- KROS 589.8M
- IPO Year
- QSI N/A
- KROS 2020
- Fundamental
- Price
- QSI $2.24
- KROS $10.86
- Analyst Decision
- QSI Buy
- KROS Buy
- Analyst Count
- QSI 2
- KROS 11
- Target Price
- QSI $3.25
- KROS $45.33
- AVG Volume (30 Days)
- QSI 60.4M
- KROS 2.0M
- Earning Date
- QSI 02-27-2025
- KROS 02-26-2025
- Dividend Yield
- QSI N/A
- KROS N/A
- EPS Growth
- QSI N/A
- KROS N/A
- EPS
- QSI N/A
- KROS N/A
- Revenue
- QSI $2,266,000.00
- KROS $651,000.00
- Revenue This Year
- QSI $193.90
- KROS $303.39
- Revenue Next Year
- QSI $173.18
- KROS N/A
- P/E Ratio
- QSI N/A
- KROS N/A
- Revenue Growth
- QSI 232.26
- KROS 8037.50
- 52 Week Low
- QSI $0.61
- KROS $9.78
- 52 Week High
- QSI $5.77
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- QSI 49.02
- KROS 20.25
- Support Level
- QSI $1.85
- KROS $9.78
- Resistance Level
- QSI $2.68
- KROS $16.49
- Average True Range (ATR)
- QSI 0.83
- KROS 0.92
- MACD
- QSI -0.15
- KROS 0.97
- Stochastic Oscillator
- QSI 9.95
- KROS 14.52
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.